The genomics market is projected to reach USD 85.09 billion by 2030 from USD 47.07 billion in 2025, registering a CAGR of 12.6% from 2025 to 2030. The growth of the genomics market is driven by increasing government funding for genomics projects, a rising prevalence of viral and inherited disorders, advancements in NGS platforms, and the expansion of applications in genomics.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=613

• In 2024, North America accounted for the largest share of 40.9% of the genomics market. The development of personalized medicine, the presence of key players in the market, and the increasing incidence of chronic diseases are some factors supporting the growth of the North American genomics market.
• By offering, the products segment accounted for the largest share of 74% of the genomics market in 2024. This dominance can primarily be attributed to the growing focus of researchers on genome sequencing projects and the increased demand for genomic products in the market.
• By technology, the sequencing segment is expected to register the highest CAGR of the genomic products market, due to its vital role in advancements in genetic research, diagnostics, and personalized medicine. Sequencing technologies, such as next-generation sequencing (NGS) and long-read sequencing, have transformed our ability to decode entire genomes. These technologies provide unmatched speed, accuracy, and depth of analysis.
• By application, the drug discovery & development segment dominates the genomics market with a share of 44.8%. The large share is due to the growing demand for personalized therapeutics, as genomics-driven drug discovery continues to gain traction, reinforcing its substantial share in the application segment.
• Illumina, Inc., Thermo Fisher Scientific Inc., and Danaher Corporation were identified as Star players in the genomics market, as they have focused on innovation and have broad industry coverage and strong operational & financial strength. Creative Biogene, Novogene Co., Ltd., and Helix, Inc. have distinguished themselves among startups and SMEs due to their strong product portfolio and business strategy.

The genomics market is experiencing steady growth, driven by advancements in next-generation sequencing (NGS) and the expanding applications of precision medicine and diagnostics. Additionally, there is an increasing amount of government and private funding for genomic research. The rising prevalence of genetic and chronic diseases, along with the integration of artificial intelligence (AI) and bioinformatics for data interpretation, is further driving market adoption across research, clinical, and pharmaceutical sectors.